[Federal Register Volume 83, Number 188 (Thursday, September 27, 2018)]
[Notices]
[Pages 48817-48818]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-21083]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC);
Meeting
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
[[Page 48818]]
CDC announces the following meeting for the Clinical Laboratory
Improvement Advisory Committee (CLIAC). This meeting is open to the
public, limited only by the space available. The meeting room
accommodates approximately 100 people. The public is also welcome to
view the meeting by webcast. Check the CLIAC website on the day of the
meeting for the webcast link http://cdclabtraining.adobeconnect.com/cliac/ cliac/.
DATES: The meeting will be held on November 7, 2018, 8:30 a.m. to 5:30
p.m., EST and November 8, 2018, 8:30 a.m. to 1:00 p.m., EST.
ADDRESSES: CDC, 2500 Century Parkway NE, Rooms 1200/1201, Atlanta,
Georgia 30345 and http://cdclabtraining.adobeconnect.com/cliac/ cliac/.
FOR FURTHER INFORMATION CONTACT: Nancy Anderson, MMSc, MT(ASCP), Senior
Advisor for Clinical Laboratories, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop F-11, Atlanta, Georgia
30329-4027, telephone (404) 498-2741; [email protected].
SUPPLEMENTARY INFORMATION: All people attending the CLIAC meeting in-
person are required to register for the meeting online at least five
business days in advance for U.S. citizens and at least 15 business
days in advance for international registrants. Register at: https://wwwn.cdc.gov/cliac/. Register by scrolling down and clicking the
``Register for this Meeting'' button and completing all forms according
to the instructions given. Please complete all the required fields
before submitting your registration and submit no later than October
30, 2018 for U.S. registrants and October 20, 2018 for international
registrants.
It is the policy of CLIAC to accept written public comments and
provide a brief period for oral public comments on agenda items. Public
comment periods for each agenda item are scheduled immediately prior to
the Committee discussion period for that item. In general, each
individual or group requesting to make oral comments will be limited to
a total time of five minutes (unless otherwise indicated). To assure
adequate time is scheduled for public comments, speakers should notify
the contact person below at least five business days prior to the
meeting date. For individuals or groups unable to attend the meeting,
CLIAC accepts written comments until the date of the meeting (unless
otherwise stated). However, it is requested that comments be submitted
at least five business days prior to the meeting date so that the
comments may be made available to the Committee for their consideration
and public distribution. Written comments, one hard copy with original
signature, should be provided to the contact person at the mailing or
email address below, and will be included in the meeting's Summary
Report.
The CLIAC meeting materials will be made available to the Committee
and the public in electronic format (PDF) on the internet instead of by
printed copy. Check the CLIAC website on the day of the meeting for
materials: https://wwwn.cdc.gov/cliac/.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services (HHS); the Assistant Secretary for Health; the Director,
Centers for Disease Control and Prevention; the Commissioner, Food and
Drug Administration (FDA); and the Administrator, Centers for Medicare
and Medicaid Services (CMS). The advice and guidance pertain to general
issues related to improvement in clinical laboratory quality and
laboratory medicine practice and specific questions related to possible
revision of the Clinical Laboratory Improvement Amendment (CLIA)
standards. Examples include providing guidance on studies designed to
improve safety, effectiveness, efficiency, timeliness, equity, and
patient-centeredness of laboratory services; revisions to the standards
under which clinical laboratories are regulated; the impact of proposed
revisions to the standards on medical and laboratory practice; and the
modification of the standards and provision of non-regulatory
guidelines to accommodate technological advances, such as new test
methods, the electronic transmission of laboratory information, and
mechanisms to improve the integration of public health and clinical
laboratory practices.
Matters To Be Considered: The agenda will include agency updates
from CDC, CMS, and FDA. Presentations and discussions will focus on an
update from the CDC's Office of Infectious Diseases Board of Scientific
Counselors meeting; updates on laboratory interoperability; updates on
antibiotic resistance activities; the Clinical Laboratory Improvement
Amendments personnel requirements; the role of the laboratory in the
opioid crisis; and the role of the laboratory in improving diagnoses.
Agenda items are subject to change as priorities dictate.
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2018-21083 Filed 9-26-18; 8:45 am]
BILLING CODE 4163-19-P